Expand CRVO Menu
CRVO MENU

CRVO Latest Press Releases

-- May 18, 2026 --

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- April 22, 2026 --

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- April 7, 2026 --

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting Globe Newswire 7:30 AM

-- March 19, 2026 --

CervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology Globe Newswire 7:30 AM

-- March 17, 2026 --

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates Globe Newswire 7:30 AM

-- March 12, 2026 --

CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference Globe Newswire 7:00 AM

-- March 5, 2026 --

CervoMed to Participate in Upcoming Investor Conferences Globe Newswire 7:30 AM

-- March 4, 2026 --

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- February 18, 2026 --

CervoMed's neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis Globe Newswire 6:00 AM

-- February 17, 2026 --

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes